Why Peregrine Pharmaceuticals Shares Skyrocketed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM  ) , a developer of monoclonal antibodies targeted at cancer therapies, soared as much as 34% after the company agreed with the Food and Drug Administration on a late-stage trial design for Bavituximab.

So what: Peregrine announced today that it's come to an agreement with the FDA for its second-line non-small-cell lung cancer immunotherapeutic treatment, Bavituximab. The trial will include about 600 people worldwide and will compare Bavituximab with docetaxel versus just docetaxel alone, with overall survival being the primary endpoint. Peregrine expects to initiate this trial before the end of the year.

Now what: This might appear to be an exorbitant move for a small-cap biotech that's merely getting the thumbs-up from the FDA to run its late-stage trial. However, if you recall, Bavituximab's road to a phase 3 trial has been wrought with controversy. First, it supposedly more than doubled survival in mid-stage trials. Then, just a few weeks later, its CEO, Steven King (no, not that one!), delivered a nightmarish tale by informing investors not to trust these results. Finally, months later, it re-released the results, demonstrating a clinical benefit again. The simple fact that the FDA agreed to Peregrine's late-stage trial is in and of itself a big success. As for me, I'm still going to keep my distance, as small-cap cancer stocks have a terrible history of phase 3 success.

Craving more input? Start by adding Peregrine Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biotechs like Peregrine Pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 20, 2013, at 6:13 PM, BSDetector wrote:

    It's not about holding through the end of phase III; it's about holding through coming upgrades, near term trial results, ASCO, and through the partnership which will undoubtly come along prior to the start of phase III in the next few months.

    Are you sure you are into this to MAKE money?

  • Report this Comment On May 20, 2013, at 9:20 PM, raulia wrote:

    PPHM will bounce more than SRPT by end of the year.It will cross $5 in next four trading session.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2441706, ~/Articles/ArticleHandler.aspx, 10/24/2014 11:03:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement